Jazz reports surprise PhIII flop for cannabinoid drug from $7.2B GW buyout
In a surprise setback, Jazz Pharmaceuticals says a cannabinoid it acquired from GW has failed a key Phase III trial.
The RELEASE MSS1 trial, which tested nabiximols oromucosal spray in patients with multiple sclerosis spasticity, did not meet the primary endpoint of change in Lower Limb Muscle Tone-6 (LLMT-6) between baseline and Day 21, the company reported, as measured by the Modified Ashworth Scale.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
